Answers are grounded in this paper and cite their sources.
BACKGROUND: mt+ NSCLC carrying a T790M resistance mutation and treated in 2nd/further lines with Osimertinib. METHODS: mt+ were captured. PFS and OS were calculated from the start of Osimertinib. RESULTS: WT (P<0.025). CONCLUSIONS: mt+ and a T790M resistance mutation treated with Osimertinib. These data, together with the data for 1st/2nd generation TKI in 1st line treatment call for additional therapeutic and management concepts for this subgroup of patients.
No takes yet. Share an insight, caveat, or question.
Roeper et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: